Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by KPOIndustrieson May 05, 2020 4:08pm
105 Views
Post# 30989685

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA

Agreed Nails, that's what bothers me about this NR. It's sloppy. If they focused on the US, defined the market like they have, but provided the material to the FDA and would've been approved by now, this thing would be flying. So I ask, why are we in the position we are? I struggle to get answers when I do "DD" because it's the same rhetoric.... phlebotomists, telehealth... but how will the test L.A. be distributed? With only two lab techs, what kind of volume will they be able to handle in the lab? And why hasn't it been approved yet? The FDA is busy, yes, but this should have been approved weeks ago based on the timeframe this news came out and where we are today. It's beyond frustrating. Maybe the market doesn't have confidence in SZLS for a reason.


Nailbiter1 wrote: I don't think Canada is a prority yet. Like the cancer tests, USA first then sloppy seconds for us Canucks. Establish then expand. Canadian phamacies were probably in sight but the Rona took care of that. Unless we have a telemed platform in Canada that we don't know of.

KPOIndustries wrote:

again, doesn't add up. Why are they seeking HC approval when they don't have a distribution network in Canada. They're relying on telehealth and the phlebotomists in the US. Again, doesn't make sense.

 

 

Florentina wrote: We are in discussions with the U.S. FDA and Health Canada. Upon approval, StageZero will announce when the formal testing begins and provide details on how to access the tests.

 

 





Bullboard Posts